We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Better Way to Deliver Dendritic Cell Vaccines

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study has shown that a new method of delivering dendritic cell vaccines is much faster and less expensive than the conventional method. More...
Conducted by scientists at the University of Texas Southwestern Medical Center (UT, Dallas, USA), the study was published in the December 28, 2002, issue of Nature Biotechnology.

Dendritic cells signal T lymphocytes to multiply and initiate an immune response against bacteria, viruses, and cancer cells and are thus good vaccine candidates. However, the conventional method of culturing cells in a petri dish is a time-consuming, expensive process that has deterred broad vaccine application. Now, a new procedure developed and tested in mice enables researchers to manipulate dendritic cells in the skin instead of a petri dish and reduces the time required from 10 days to 24 hours.

Here is how the new delivery method works. Upon exposure to the chemical hapten, immature dendritic cells in the epidermis known as Langerhans cells mature and migrate to draining lymph nodes. A key chemokine (MIP3beta) helps to attract the migrating cells and mediate the migration process. The researchers created an artificial trap for Langerhans cells by implanting a polymer rod under the skin that was synthesized with ethylene-vinyl-acetate to release this chemokine. After the rod was implanted, hapten was applied to trigger the Langerhans cell migration. The cells homed in to the lymph nodes and created an accumulation of Langerhans cells around the rod.

In a second experiment, the researchers utilized a polymer rod releasing a tumor-associated antigen that was implanted under the skin, believing that the Langerhans cells would carry the antigen to the draining lymph nodes and initiate immunity against tumor development. Subsequent experiments with different tumor models have demonstrated that this strategy is efficacious.

"We believe that our in situ Langerhans cell vaccine format represents a breakthrough in the tumor vaccines field, thus moving it toward practical medicine,” said Dr. Akira Takashima, professor of dermatology at UT Southwestern.




Related Links:
University of Texas Southwestern Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.